Erectile Dysfunction Drugs Market Share Analysis Report, 2022-2030
The global Erectile Dysfunction Drugs market size was estimated at USD 2.31 billion in 2021 and is expected to surpass around USD 4.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.6% during the forecast period 2022 to 2030.
Growth Factors:
The increasing burden of lifestyle diseases and rising adoption of a sedentary lifestyle are responsible for the increasing incidence of Erectile Dysfunction (ED) worldwide. According to World Health Organization (WHO) report, around 15% of the male population were reported to be affected by erectile dysfunction every year which is projected to reach 320 million by 2025. Hence, increasing disease prevalence and rising demand for ED medicines are among the key factors driving the growth of the market. The COVID-19 pandemic had a positive impact on the sales of erectile dysfunction drugs owing to increased demand for products.
According to the University of Pittsburgh's School of Medicine, there was high growth in sales of erectile dysfunction drugs due to the government-imposed lockdown in 2020. Among all ED drugs, Cialis (Tadalafil) witnessed significant growth in sales in the U.S. Moreover, other factors such as easy access to ED drugs supported the growth of the market for erectile dysfunction drugs. Currently, various drugs are used to manage erectile dysfunction including, sildenafil (Revatio, Viagra), vardenafil (Levitra, Staxyn), tadalafil (Adcirca, Cialis), and avanafil (Stendra) among others.
Depending on the dose, generic sildenafil is frequently offered for a significantly lesser cost than Viagra, which typically costs around USD 70 per pill. Therefore, the availability of affordable medications may lead to higher prescription rates and market expansion. Considerably, the prevalence of ED is increasing with age due to comorbid conditions such as diabetes, obesity, and others. Men with medication, hormonal, neurological, and vascular etiologies are also at a high-risk development of disease.
A lifetime ED episode was experienced by around 35 -75% of male diabetic patients, according to the WHO. By 2021, there were 422 million diabetic patients living in low- and middle-income nations. However, the market growth could be hampered by a lack of healthcare infrastructure and manufacturing mistakes. For instance, Sun Pharmaceutical Industries Ltd. announced the recall of its generic drug Tadalafil in November 2021 as a result of a production fault. This recall could leave a small gap in the supply of ED generic drugs used to treat erectile dysfunction patients.
Report Scope of the Erectile Dysfunction Drugs Market
|
Report Coverage |
Details |
|
Market Size |
US$ 4.9 Billion by 2030 |
|
Growth Rate |
CAGR of 8.6% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product and Region, |
|
Companies Mentioned |
Pfizer, Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd; Sanofi; Sun Pharmaceutical Industries Ltd; Bayer AG; Petros Pharmaceuticals, Inc., VIVUS, Inc.; Auxilium Pharmaceuticals, Inc., Adamed |
Product Insights
The viagra segment held the highest revenue share of 57.9% in 2021. At present, many companies are undertaking various strategic initiatives such as research collaboration, partnerships, and agreements with an aim to expand their business footprint. For instance, in January 2020, Pfizer, Inc., and Digital Men’s Clinic Roman signed a supply agreement to provide a generic version of Viagra to roman members. This supply agreement is expected to boost the growth of the segment.
The others segment is also expected to witness lucrative market growth over the forecast period owing to the large application base and availability of ED medicines, such as Helleva (lodenafil carbonate), Mvix (mirodenafil), and others that are also used to treat adult patients with erectile dysfunction. Increasing approval of over-the-counter ED products offers easy access to ED patients. For instance, in February 2022, Adamed was the first-ever polish company that received marketing authorization approval for Tadalafil MAXON from prescription to over-the-counter (OTC) category. Hence, the introduction of such products in the market may boost the utilization of ED drugs.
Regional Insights
North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.8% in 2021 due to the high burden of disease, strong healthcare infrastructure, and approval of new products for treatment. In March 2022, Lupin received the U.S. FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent to Revatio of Viatris Specialty LLC. The accessibility of affordable generic products may increase patient compliance, consequently, increasing the consumer base and revenue for the market
In Asia Pacific, the market for erectile dysfunction drugs is expected to witness fast growth during the forecast period. The growth of the region is attributable to the entry of new products into the region. For instance, in May 2020, iX Biopharma announced the supply of Wafesil and Silcap through telemedicine in Australia for the treatment of an adult patient with erectile dysfunction.
Some of the prominent players in the Erectile Dysfunction Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Erectile Dysfunction Drugs market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Erectile Dysfunction Drugs Market Study:
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 Nova one advisor’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation and Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Erectile Dysfunction Drugs Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Covid Impact Analysis
3.5 Market Dynamics
3.6 Market Driver Impact Analysis
3.6.1 Increasing prevalence of erectile dysfunction
3.6.2 Increasing product approval and launches
3.6.3 Supportive reimbursement policies
3.7 Market Restraint Analysis
3.7.1 Lack of healthcare infrastructure and manufacturing errors
3.7.2 Lack of awareness about the condition
3.8 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.9 Porter’s Five Forces Analysis
Chapter 4 Erectile Dysfunction Drugs Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)
4.1 Erectile Dysfunction Drugs Market: Product Movement Analysis
4.1.1 Viagra
4.1.1.1 Viagra market estimates and forecast, 2018 - 2030
4.1.2 Cialis
4.1.2.1 Cialis market estimates and forecast, 2018 - 2030
4.1.3 Zydena
4.1.3.1 Zydena market estimates and forecast, 2018 - 2030
4.1.4 Levitra
4.1.4.1 Levitra market estimates and forecast, 2018 - 2030
4.1.5 Stendra
4.1.5.1 Stendra market estimates and forecast, 2018 - 2030
4.1.6 Others
4.1.6.1 Others market estimates and forecast, 2018 - 2030
Chapter 5 Erectile Dysfunction Drugs Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)
5.1 Regional Market Share Analysis, 2021 & 2030
5.2 Regional Market Snapshot
5.3 Market Size, Forecasts, and Revenue & Trend Analysis, 2021 to 2030
5.3.1 North America
5.3.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
5.3.1.2 U.S.
5.3.1.2.1 U.S. Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.1.3 Canada
5.3.1.3.1 Canada Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2 Europe
5.3.2.1 Europe Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.2 U.K.
5.3.2.2.1 U.K. Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.3 Germany
5.3.2.3.1 Germany Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.4 Spain
5.3.2.4.1 Spain Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.5 France
5.3.2.5.1 France Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.6 Italy
5.3.2.6.1 Italy Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3 Asia Pacific
5.3.3.1 Asia Pacific Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.2 Japan
5.3.3.2.1 Japan Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.3 China
5.3.3.3.1 China Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.4 India
5.3.3.4.1 India Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.5 Australia
5.3.3.5.1 Australia Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4 Latin America
5.3.4.1 Latin America Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.2 Brazil
5.3.4.2.1 Brazil Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.3 Mexico
5.3.4.3.1 Mexico Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.4 Argentina
5.3.4.4.1 Argentina Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5 MEA
5.3.5.1 MEA Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.2 South Africa
5.3.5.2.1 South Africa Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.3 Saudi Arabia
5.3.5.3.1 Saudia Arabia Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.4 UAE
5.3.5.4.1 UAE Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
Chapter 6 Erectile Dysfunction Drugs Market: Competitive Analysis
6.1 Recent Developments and Impact Analysis, by Key Market Participants
6.1.1 Synergy Analysis: Major Deals and Strategic Alliances
6.1.1.1 New Product Launches
6.1.1.2 Mergers and Acquisitions
6.1.1.3 Licensing Agreements
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.2.3 Emerging Players
6.2.4 Heat map analysis
6.3 Company Market Position Analysis
6.4 Vendor Landscape
6.4.1 List of key distributors and channel partners
6.4.2 List of Potential End-Users
6.4.3 Key Company Market Share Analysis, 2021
6.4.4 Consumer Behavior Analysis
6.4.5 Competitive Dashboard Analysis
6.5 Private Companies
6.5.1 List of key emerging companies
6.5.2 Regional Network Map
6.6 Company Profiles
6.6.1 Pfizer, Inc.
6.6.1.1 Company overview
6.6.1.2 Financial Performance
6.6.1.3 Product benchmarking
6.6.1.4 Strategic initiatives
6.6.2 Eli Lilly and Company
6.6.2.1 Company overview
6.6.2.2 Financial Performance
6.6.2.3 Product benchmarking
6.6.2.4 Strategic initiatives
6.6.3 Teva Pharmaceutical Industries Ltd
6.6.3.1 Company overview
6.6.3.2 Financial Performance
6.6.3.3 Product benchmarking
6.6.3.4 Strategic initiatives
6.6.4 Sanofi
6.6.4.1 Company overview
6.6.4.2 Financial Performance
6.6.4.3 Product benchmarking
6.6.4.4 Strategic initiatives
6.6.5 Sun Pharmaceutical Industries Ltd
6.6.5.1 Company overview
6.6.5.2 Financial Performance
6.6.5.3 Product benchmarking
6.6.5.4 Strategic initiatives
6.6.6 Bayer AG
6.6.6.1 Company overview
6.6.6.2 Financial Performance
6.6.6.3 Product benchmarking
6.6.6.4 Strategic initiatives
6.6.7 Petros Pharmaceuticals, Inc.
6.6.7.1 Company overview
6.6.7.2 Financial Performance
6.6.7.3 Product benchmarking
6.6.7.4 Strategic initiatives
6.6.8 VIVUS, Inc.
6.6.8.1 Company overview
6.6.8.2 Financial Performance
6.6.8.3 Product benchmarking
6.6.8.4 Strategic initiatives
6.6.9 Auxilium Pharmaceuticals, Inc.
6.6.9.1 Company overview
6.6.9.2 Financial Performance
6.6.9.3 Product benchmarking
6.6.9.4 Strategic initiatives
6.6.10 Adamed
6.6.10.1 Company overview
6.6.10.2 Financial Performance
6.6.10.3 Product benchmarking
6.6.10.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers